PSMA-PET follow-up to assess response in patients not receiving PSMA therapy: Is there value beyond localization of disease?
Prostate Specific Membrane Antigen Positron Emission Tomography (PSMA-PET) is routinely used for the staging of patients with prostate cancer, but data on response assessment are sparse and primarily stem from metastatic castration-resistant prostate cancer (mCRPC) patients treated with PSMA radioli...
Gespeichert in:
| Veröffentlicht in: | Theranostics 2024-01, Vol.14 (9), p.3623-3633 |
|---|---|
| Hauptverfasser: | , , , , , , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 3633 |
|---|---|
| container_issue | 9 |
| container_start_page | 3623 |
| container_title | Theranostics |
| container_volume | 14 |
| creator | Küper, Alina T Kersting, David Telli, Tugce Herrmann, Ken Rominger, Axel Afshar-Oromieh, Ali Lopes, Leonor Karkampouna, Sofia Shi, Kuangyu Kim, Moon Hadaschik, Boris Darr, Christopher Umutlu, Lale Fendler, Wolfgang P Seifert, Robert |
| description | Prostate Specific Membrane Antigen Positron Emission Tomography (PSMA-PET) is routinely used for the staging of patients with prostate cancer, but data on response assessment are sparse and primarily stem from metastatic castration-resistant prostate cancer (mCRPC) patients treated with PSMA radioligand therapy. Still, follow-up PSMA-PET is employed in earlier disease stages in case of clinical suspicion of disease persistence, recurrence or progression to decide if localized or systemic treatment is indicated. Therefore, the prognostic value of PSMA-PET derived tumor volumes in earlier disease stages (i.e., hormone-sensitive prostate cancer (HSPC) and non-[
Lu]Lu-PSMA-617 (LuPSMA) therapy castration resistant prostate cancer (CRPC)) are evaluated in this manuscript.
A total number of 73 patients (6 primary staging, 42 HSPC, 25 CRPC) underwent two (i.e., baseline and follow-up, median interval: 379 days) whole-body [
Ga]Ga-PSMA-11 PET/CT scans between Nov 2014 and Dec 2018. Analysis was restricted to non-LuPSMA therapy patients. PSMA-PETs were retrospectively analyzed and primary tumor, lymph node-, visceral-, and bone metastases were segmented. Body weight-adjusted organ-specific and total tumor volumes (PSMAvol: sum of PET volumes of all lesions) were measured for baseline and follow-up. PSMAvol response was calculated as the absolute difference of whole-body tumor volumes. High metastatic burden (>5 metastases), RECIP 1.0 and PSMA-PET Progression Criteria (PPP) were determined. Survival data were sourced from the cancer registry.
The average number of tumor lesions per patient on the initial PET examination was 10.3 (SD 28.4). At baseline, PSMAvol was strongly associated with OS (HR 3.92, p |
| doi_str_mv | 10.7150/thno.96738 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_11209722</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>3074136950</sourcerecordid><originalsourceid>FETCH-LOGICAL-c268t-4cc2d57fc8609f178a700601fc110bd154db86c0f37eb112b0543a6b16dfaae93</originalsourceid><addsrcrecordid>eNpVkV1LHTEQhkNpqWK96Q8ouZTCarLZTbK9ERG_wKKgXodsduJJyUnWnd1TTvHHu0et6NzMwLzzzAwvId8521e8ZgfjIuX9RiqhP5FtroUulKzY53f1FtlF_MPmqFjZ8OYr2RK6qTSr623yeH3z-6i4PrmlPseY_xZTT8dMLSIg0gGwzwmBhkR7OwZII9KUx7nhIKxCuqebeTouYLD9-he9wOca6MrGCWgL65w6GrOzMfybATnR7GkXECzC4TfyxduIsPuad8jd6cnt8XlxeXV2cXx0WbhS6rGonCu7WnmnJWs8V9oqxiTj3nHO2o7XVddq6ZgXClrOy5bVlbCy5bLz1kIjdsjhC7ef2iV0bn5jsNH0Q1jaYW2yDeZjJ4WFuc8rM8NYo8pyJuy9Eob8MAGOZhnQQYw2QZ7QCKYqLmRTs1n680Xqhow4gH_bw5nZWGY2lplny2bxj_eXvUn_GySeAOaylA8</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>3074136950</pqid></control><display><type>article</type><title>PSMA-PET follow-up to assess response in patients not receiving PSMA therapy: Is there value beyond localization of disease?</title><source>MEDLINE</source><source>EZB-FREE-00999 freely available EZB journals</source><source>PubMed Central</source><source>PubMed Central Open Access</source><creator>Küper, Alina T ; Kersting, David ; Telli, Tugce ; Herrmann, Ken ; Rominger, Axel ; Afshar-Oromieh, Ali ; Lopes, Leonor ; Karkampouna, Sofia ; Shi, Kuangyu ; Kim, Moon ; Hadaschik, Boris ; Darr, Christopher ; Umutlu, Lale ; Fendler, Wolfgang P ; Seifert, Robert</creator><creatorcontrib>Küper, Alina T ; Kersting, David ; Telli, Tugce ; Herrmann, Ken ; Rominger, Axel ; Afshar-Oromieh, Ali ; Lopes, Leonor ; Karkampouna, Sofia ; Shi, Kuangyu ; Kim, Moon ; Hadaschik, Boris ; Darr, Christopher ; Umutlu, Lale ; Fendler, Wolfgang P ; Seifert, Robert</creatorcontrib><description><![CDATA[Prostate Specific Membrane Antigen Positron Emission Tomography (PSMA-PET) is routinely used for the staging of patients with prostate cancer, but data on response assessment are sparse and primarily stem from metastatic castration-resistant prostate cancer (mCRPC) patients treated with PSMA radioligand therapy. Still, follow-up PSMA-PET is employed in earlier disease stages in case of clinical suspicion of disease persistence, recurrence or progression to decide if localized or systemic treatment is indicated. Therefore, the prognostic value of PSMA-PET derived tumor volumes in earlier disease stages (i.e., hormone-sensitive prostate cancer (HSPC) and non-[
Lu]Lu-PSMA-617 (LuPSMA) therapy castration resistant prostate cancer (CRPC)) are evaluated in this manuscript.
A total number of 73 patients (6 primary staging, 42 HSPC, 25 CRPC) underwent two (i.e., baseline and follow-up, median interval: 379 days) whole-body [
Ga]Ga-PSMA-11 PET/CT scans between Nov 2014 and Dec 2018. Analysis was restricted to non-LuPSMA therapy patients. PSMA-PETs were retrospectively analyzed and primary tumor, lymph node-, visceral-, and bone metastases were segmented. Body weight-adjusted organ-specific and total tumor volumes (PSMAvol: sum of PET volumes of all lesions) were measured for baseline and follow-up. PSMAvol response was calculated as the absolute difference of whole-body tumor volumes. High metastatic burden (>5 metastases), RECIP 1.0 and PSMA-PET Progression Criteria (PPP) were determined. Survival data were sourced from the cancer registry.
The average number of tumor lesions per patient on the initial PET examination was 10.3 (SD 28.4). At baseline, PSMAvol was strongly associated with OS (HR 3.92, p <0.001; n = 73). Likewise, response in PSMAvol was significantly associated with OS (HR 10.48, p < 0.005; n = 73). PPP achieved significance as well (HR 2.19, p <0.05, n = 73). Patients with hormone sensitive disease and poor PSMAvol response (upper quartile of PSMAvol change) in follow-up had shorter outcome (p < 0.05; n = 42). PSMAvol in bones was the most relevant parameter for OS prognostication at baseline and for response assessment (HR 31.11 p < 0.001; HR 32.27, p < 0.001; n = 73).
PPP and response in PSMAvol were significantly associated with OS in the present heterogeneous cohort. Bone tumor volume was the relevant miTNM region for OS prognostication. Future prospective evaluation of the performance of organ specific PSMAvol in more homogeneous cohorts seems warranted.]]></description><identifier>ISSN: 1838-7640</identifier><identifier>EISSN: 1838-7640</identifier><identifier>DOI: 10.7150/thno.96738</identifier><identifier>PMID: 38948055</identifier><language>eng</language><publisher>Australia: Ivyspring International Publisher</publisher><subject>Aged ; Aged, 80 and over ; Antigens, Surface - metabolism ; Dipeptides - therapeutic use ; Follow-Up Studies ; Gallium Isotopes ; Gallium Radioisotopes ; Glutamate Carboxypeptidase II - metabolism ; Heterocyclic Compounds, 1-Ring - therapeutic use ; Humans ; Lutetium - therapeutic use ; Male ; Middle Aged ; Positron Emission Tomography Computed Tomography - methods ; Positron-Emission Tomography - methods ; Prognosis ; Prostatic Neoplasms - diagnostic imaging ; Prostatic Neoplasms - pathology ; Prostatic Neoplasms, Castration-Resistant - diagnostic imaging ; Prostatic Neoplasms, Castration-Resistant - pathology ; Radiopharmaceuticals ; Research Paper ; Retrospective Studies ; Tumor Burden</subject><ispartof>Theranostics, 2024-01, Vol.14 (9), p.3623-3633</ispartof><rights>The author(s).</rights><rights>The author(s) 2024</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC11209722/pdf/$$EPDF$$P50$$Gpubmedcentral$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC11209722/$$EHTML$$P50$$Gpubmedcentral$$Hfree_for_read</linktohtml><link.rule.ids>230,314,723,776,780,881,27901,27902,53766,53768</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/38948055$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Küper, Alina T</creatorcontrib><creatorcontrib>Kersting, David</creatorcontrib><creatorcontrib>Telli, Tugce</creatorcontrib><creatorcontrib>Herrmann, Ken</creatorcontrib><creatorcontrib>Rominger, Axel</creatorcontrib><creatorcontrib>Afshar-Oromieh, Ali</creatorcontrib><creatorcontrib>Lopes, Leonor</creatorcontrib><creatorcontrib>Karkampouna, Sofia</creatorcontrib><creatorcontrib>Shi, Kuangyu</creatorcontrib><creatorcontrib>Kim, Moon</creatorcontrib><creatorcontrib>Hadaschik, Boris</creatorcontrib><creatorcontrib>Darr, Christopher</creatorcontrib><creatorcontrib>Umutlu, Lale</creatorcontrib><creatorcontrib>Fendler, Wolfgang P</creatorcontrib><creatorcontrib>Seifert, Robert</creatorcontrib><title>PSMA-PET follow-up to assess response in patients not receiving PSMA therapy: Is there value beyond localization of disease?</title><title>Theranostics</title><addtitle>Theranostics</addtitle><description><![CDATA[Prostate Specific Membrane Antigen Positron Emission Tomography (PSMA-PET) is routinely used for the staging of patients with prostate cancer, but data on response assessment are sparse and primarily stem from metastatic castration-resistant prostate cancer (mCRPC) patients treated with PSMA radioligand therapy. Still, follow-up PSMA-PET is employed in earlier disease stages in case of clinical suspicion of disease persistence, recurrence or progression to decide if localized or systemic treatment is indicated. Therefore, the prognostic value of PSMA-PET derived tumor volumes in earlier disease stages (i.e., hormone-sensitive prostate cancer (HSPC) and non-[
Lu]Lu-PSMA-617 (LuPSMA) therapy castration resistant prostate cancer (CRPC)) are evaluated in this manuscript.
A total number of 73 patients (6 primary staging, 42 HSPC, 25 CRPC) underwent two (i.e., baseline and follow-up, median interval: 379 days) whole-body [
Ga]Ga-PSMA-11 PET/CT scans between Nov 2014 and Dec 2018. Analysis was restricted to non-LuPSMA therapy patients. PSMA-PETs were retrospectively analyzed and primary tumor, lymph node-, visceral-, and bone metastases were segmented. Body weight-adjusted organ-specific and total tumor volumes (PSMAvol: sum of PET volumes of all lesions) were measured for baseline and follow-up. PSMAvol response was calculated as the absolute difference of whole-body tumor volumes. High metastatic burden (>5 metastases), RECIP 1.0 and PSMA-PET Progression Criteria (PPP) were determined. Survival data were sourced from the cancer registry.
The average number of tumor lesions per patient on the initial PET examination was 10.3 (SD 28.4). At baseline, PSMAvol was strongly associated with OS (HR 3.92, p <0.001; n = 73). Likewise, response in PSMAvol was significantly associated with OS (HR 10.48, p < 0.005; n = 73). PPP achieved significance as well (HR 2.19, p <0.05, n = 73). Patients with hormone sensitive disease and poor PSMAvol response (upper quartile of PSMAvol change) in follow-up had shorter outcome (p < 0.05; n = 42). PSMAvol in bones was the most relevant parameter for OS prognostication at baseline and for response assessment (HR 31.11 p < 0.001; HR 32.27, p < 0.001; n = 73).
PPP and response in PSMAvol were significantly associated with OS in the present heterogeneous cohort. Bone tumor volume was the relevant miTNM region for OS prognostication. Future prospective evaluation of the performance of organ specific PSMAvol in more homogeneous cohorts seems warranted.]]></description><subject>Aged</subject><subject>Aged, 80 and over</subject><subject>Antigens, Surface - metabolism</subject><subject>Dipeptides - therapeutic use</subject><subject>Follow-Up Studies</subject><subject>Gallium Isotopes</subject><subject>Gallium Radioisotopes</subject><subject>Glutamate Carboxypeptidase II - metabolism</subject><subject>Heterocyclic Compounds, 1-Ring - therapeutic use</subject><subject>Humans</subject><subject>Lutetium - therapeutic use</subject><subject>Male</subject><subject>Middle Aged</subject><subject>Positron Emission Tomography Computed Tomography - methods</subject><subject>Positron-Emission Tomography - methods</subject><subject>Prognosis</subject><subject>Prostatic Neoplasms - diagnostic imaging</subject><subject>Prostatic Neoplasms - pathology</subject><subject>Prostatic Neoplasms, Castration-Resistant - diagnostic imaging</subject><subject>Prostatic Neoplasms, Castration-Resistant - pathology</subject><subject>Radiopharmaceuticals</subject><subject>Research Paper</subject><subject>Retrospective Studies</subject><subject>Tumor Burden</subject><issn>1838-7640</issn><issn>1838-7640</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2024</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNpVkV1LHTEQhkNpqWK96Q8ouZTCarLZTbK9ERG_wKKgXodsduJJyUnWnd1TTvHHu0et6NzMwLzzzAwvId8521e8ZgfjIuX9RiqhP5FtroUulKzY53f1FtlF_MPmqFjZ8OYr2RK6qTSr623yeH3z-6i4PrmlPseY_xZTT8dMLSIg0gGwzwmBhkR7OwZII9KUx7nhIKxCuqebeTouYLD9-he9wOca6MrGCWgL65w6GrOzMfybATnR7GkXECzC4TfyxduIsPuad8jd6cnt8XlxeXV2cXx0WbhS6rGonCu7WnmnJWs8V9oqxiTj3nHO2o7XVddq6ZgXClrOy5bVlbCy5bLz1kIjdsjhC7ef2iV0bn5jsNH0Q1jaYW2yDeZjJ4WFuc8rM8NYo8pyJuy9Eob8MAGOZhnQQYw2QZ7QCKYqLmRTs1n680Xqhow4gH_bw5nZWGY2lplny2bxj_eXvUn_GySeAOaylA8</recordid><startdate>20240101</startdate><enddate>20240101</enddate><creator>Küper, Alina T</creator><creator>Kersting, David</creator><creator>Telli, Tugce</creator><creator>Herrmann, Ken</creator><creator>Rominger, Axel</creator><creator>Afshar-Oromieh, Ali</creator><creator>Lopes, Leonor</creator><creator>Karkampouna, Sofia</creator><creator>Shi, Kuangyu</creator><creator>Kim, Moon</creator><creator>Hadaschik, Boris</creator><creator>Darr, Christopher</creator><creator>Umutlu, Lale</creator><creator>Fendler, Wolfgang P</creator><creator>Seifert, Robert</creator><general>Ivyspring International Publisher</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope><scope>5PM</scope></search><sort><creationdate>20240101</creationdate><title>PSMA-PET follow-up to assess response in patients not receiving PSMA therapy: Is there value beyond localization of disease?</title><author>Küper, Alina T ; Kersting, David ; Telli, Tugce ; Herrmann, Ken ; Rominger, Axel ; Afshar-Oromieh, Ali ; Lopes, Leonor ; Karkampouna, Sofia ; Shi, Kuangyu ; Kim, Moon ; Hadaschik, Boris ; Darr, Christopher ; Umutlu, Lale ; Fendler, Wolfgang P ; Seifert, Robert</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c268t-4cc2d57fc8609f178a700601fc110bd154db86c0f37eb112b0543a6b16dfaae93</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2024</creationdate><topic>Aged</topic><topic>Aged, 80 and over</topic><topic>Antigens, Surface - metabolism</topic><topic>Dipeptides - therapeutic use</topic><topic>Follow-Up Studies</topic><topic>Gallium Isotopes</topic><topic>Gallium Radioisotopes</topic><topic>Glutamate Carboxypeptidase II - metabolism</topic><topic>Heterocyclic Compounds, 1-Ring - therapeutic use</topic><topic>Humans</topic><topic>Lutetium - therapeutic use</topic><topic>Male</topic><topic>Middle Aged</topic><topic>Positron Emission Tomography Computed Tomography - methods</topic><topic>Positron-Emission Tomography - methods</topic><topic>Prognosis</topic><topic>Prostatic Neoplasms - diagnostic imaging</topic><topic>Prostatic Neoplasms - pathology</topic><topic>Prostatic Neoplasms, Castration-Resistant - diagnostic imaging</topic><topic>Prostatic Neoplasms, Castration-Resistant - pathology</topic><topic>Radiopharmaceuticals</topic><topic>Research Paper</topic><topic>Retrospective Studies</topic><topic>Tumor Burden</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Küper, Alina T</creatorcontrib><creatorcontrib>Kersting, David</creatorcontrib><creatorcontrib>Telli, Tugce</creatorcontrib><creatorcontrib>Herrmann, Ken</creatorcontrib><creatorcontrib>Rominger, Axel</creatorcontrib><creatorcontrib>Afshar-Oromieh, Ali</creatorcontrib><creatorcontrib>Lopes, Leonor</creatorcontrib><creatorcontrib>Karkampouna, Sofia</creatorcontrib><creatorcontrib>Shi, Kuangyu</creatorcontrib><creatorcontrib>Kim, Moon</creatorcontrib><creatorcontrib>Hadaschik, Boris</creatorcontrib><creatorcontrib>Darr, Christopher</creatorcontrib><creatorcontrib>Umutlu, Lale</creatorcontrib><creatorcontrib>Fendler, Wolfgang P</creatorcontrib><creatorcontrib>Seifert, Robert</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Theranostics</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Küper, Alina T</au><au>Kersting, David</au><au>Telli, Tugce</au><au>Herrmann, Ken</au><au>Rominger, Axel</au><au>Afshar-Oromieh, Ali</au><au>Lopes, Leonor</au><au>Karkampouna, Sofia</au><au>Shi, Kuangyu</au><au>Kim, Moon</au><au>Hadaschik, Boris</au><au>Darr, Christopher</au><au>Umutlu, Lale</au><au>Fendler, Wolfgang P</au><au>Seifert, Robert</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>PSMA-PET follow-up to assess response in patients not receiving PSMA therapy: Is there value beyond localization of disease?</atitle><jtitle>Theranostics</jtitle><addtitle>Theranostics</addtitle><date>2024-01-01</date><risdate>2024</risdate><volume>14</volume><issue>9</issue><spage>3623</spage><epage>3633</epage><pages>3623-3633</pages><issn>1838-7640</issn><eissn>1838-7640</eissn><abstract><![CDATA[Prostate Specific Membrane Antigen Positron Emission Tomography (PSMA-PET) is routinely used for the staging of patients with prostate cancer, but data on response assessment are sparse and primarily stem from metastatic castration-resistant prostate cancer (mCRPC) patients treated with PSMA radioligand therapy. Still, follow-up PSMA-PET is employed in earlier disease stages in case of clinical suspicion of disease persistence, recurrence or progression to decide if localized or systemic treatment is indicated. Therefore, the prognostic value of PSMA-PET derived tumor volumes in earlier disease stages (i.e., hormone-sensitive prostate cancer (HSPC) and non-[
Lu]Lu-PSMA-617 (LuPSMA) therapy castration resistant prostate cancer (CRPC)) are evaluated in this manuscript.
A total number of 73 patients (6 primary staging, 42 HSPC, 25 CRPC) underwent two (i.e., baseline and follow-up, median interval: 379 days) whole-body [
Ga]Ga-PSMA-11 PET/CT scans between Nov 2014 and Dec 2018. Analysis was restricted to non-LuPSMA therapy patients. PSMA-PETs were retrospectively analyzed and primary tumor, lymph node-, visceral-, and bone metastases were segmented. Body weight-adjusted organ-specific and total tumor volumes (PSMAvol: sum of PET volumes of all lesions) were measured for baseline and follow-up. PSMAvol response was calculated as the absolute difference of whole-body tumor volumes. High metastatic burden (>5 metastases), RECIP 1.0 and PSMA-PET Progression Criteria (PPP) were determined. Survival data were sourced from the cancer registry.
The average number of tumor lesions per patient on the initial PET examination was 10.3 (SD 28.4). At baseline, PSMAvol was strongly associated with OS (HR 3.92, p <0.001; n = 73). Likewise, response in PSMAvol was significantly associated with OS (HR 10.48, p < 0.005; n = 73). PPP achieved significance as well (HR 2.19, p <0.05, n = 73). Patients with hormone sensitive disease and poor PSMAvol response (upper quartile of PSMAvol change) in follow-up had shorter outcome (p < 0.05; n = 42). PSMAvol in bones was the most relevant parameter for OS prognostication at baseline and for response assessment (HR 31.11 p < 0.001; HR 32.27, p < 0.001; n = 73).
PPP and response in PSMAvol were significantly associated with OS in the present heterogeneous cohort. Bone tumor volume was the relevant miTNM region for OS prognostication. Future prospective evaluation of the performance of organ specific PSMAvol in more homogeneous cohorts seems warranted.]]></abstract><cop>Australia</cop><pub>Ivyspring International Publisher</pub><pmid>38948055</pmid><doi>10.7150/thno.96738</doi><tpages>11</tpages><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1838-7640 |
| ispartof | Theranostics, 2024-01, Vol.14 (9), p.3623-3633 |
| issn | 1838-7640 1838-7640 |
| language | eng |
| recordid | cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_11209722 |
| source | MEDLINE; EZB-FREE-00999 freely available EZB journals; PubMed Central; PubMed Central Open Access |
| subjects | Aged Aged, 80 and over Antigens, Surface - metabolism Dipeptides - therapeutic use Follow-Up Studies Gallium Isotopes Gallium Radioisotopes Glutamate Carboxypeptidase II - metabolism Heterocyclic Compounds, 1-Ring - therapeutic use Humans Lutetium - therapeutic use Male Middle Aged Positron Emission Tomography Computed Tomography - methods Positron-Emission Tomography - methods Prognosis Prostatic Neoplasms - diagnostic imaging Prostatic Neoplasms - pathology Prostatic Neoplasms, Castration-Resistant - diagnostic imaging Prostatic Neoplasms, Castration-Resistant - pathology Radiopharmaceuticals Research Paper Retrospective Studies Tumor Burden |
| title | PSMA-PET follow-up to assess response in patients not receiving PSMA therapy: Is there value beyond localization of disease? |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-01T14%3A31%3A16IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=PSMA-PET%20follow-up%20to%20assess%20response%20in%20patients%20not%20receiving%20PSMA%20therapy:%20Is%20there%20value%20beyond%20localization%20of%20disease?&rft.jtitle=Theranostics&rft.au=K%C3%BCper,%20Alina%20T&rft.date=2024-01-01&rft.volume=14&rft.issue=9&rft.spage=3623&rft.epage=3633&rft.pages=3623-3633&rft.issn=1838-7640&rft.eissn=1838-7640&rft_id=info:doi/10.7150/thno.96738&rft_dat=%3Cproquest_pubme%3E3074136950%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=3074136950&rft_id=info:pmid/38948055&rfr_iscdi=true |